ALLMedicine™ Viral Hepatitis Center
Research & Reviews 2,854 results
https://clinicaltrials.gov/ct2/show/NCT01350648
Feb 3rd, 2023 - Chronic viral hepatitis is a major health problem affecting millions globally. The immunosuppressed population, especially those with HIV infection, remains at particular risk and the incidence of hepatocellular carcinoma (HCC) is increasing in th...
https://clinicaltrials.gov/ct2/show/NCT01036971
Feb 3rd, 2023 - This protocol describes the screening process used by the National Institute on Drug Abuse (NIDA IRP) to assess potential research participants' eligibility for entering protocols of the NIDA/IRP. Through its clinical research protocols, the IRP a...
https://doi.org/10.1097/MCG.0000000000001784
Journal of Clinical Gastroenterology; No JS, Buckholz A et. al.
Feb 3rd, 2023 - Patients with metabolic syndrome (MetS) are likely to have nonalcoholic fatty liver disease (NAFLD), which can progress to advanced fibrosis. Early recognition of those at highest risk may ameliorate outcomes. Noninvasive liver fibrosis assessment...
https://clinicaltrials.gov/ct2/show/NCT04409340
Feb 1st, 2023 - RESEARCH QUESTION AND BACKGROUND: Primary liver cancer or hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women and is the second cause of cancer mortality worldwide. In Canada, HCC is the only cancer for w...
https://clinicaltrials.gov/ct2/show/NCT05676177
Jan 31st, 2023 - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. It affects 25% of the global population, with a higher proportion in Middle Eastern countries, especially in individuals with type 2 diabetes mellitus (T2...
Guidelines 9 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009216
Journal for Immunotherapy of Cancer; Gonzalez-Cao M, Puertolas T et. al.
Mar 31st, 2021 - Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other t...
https://doi.org/10.1111/jdv.16926
Journal of the European Academy of Dermatology and Venere... Nast A, Smith C et. al.
Feb 7th, 2021 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clini...
https://doi.org/10.5604/16652681.1226808
Annals of Hepatology; Brahm J, Castera L et. al.
Jan 5th, 2017 - Joint Society statement for elimination of viral hepatitis.|2017|Brahm J,Castera L,Hou J,Lindor K,|standards,diagnosis,mortality,prevention & control,virology,standards,standards,standards,
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.
Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...
https://doi.org/10.1016/j.jhep.2016.08.002
Journal of Hepatology; Easterbrook PJ,
Sep 20th, 2016 - Testing and diagnosis of hepatitis C virus (HCV) infection is the gateway for access to both treatment and prevention services, and crucial for an effective hepatitis epidemic response. In contrast to HIV, a systematic approach to hepatitis C test...
Drugs 6 results see all →
Clinicaltrials.gov 255 results
https://clinicaltrials.gov/ct2/show/NCT01036971
Feb 3rd, 2023 - This protocol describes the screening process used by the National Institute on Drug Abuse (NIDA IRP) to assess potential research participants' eligibility for entering protocols of the NIDA/IRP. Through its clinical research protocols, the IRP a...
https://clinicaltrials.gov/ct2/show/NCT01350648
Feb 3rd, 2023 - Chronic viral hepatitis is a major health problem affecting millions globally. The immunosuppressed population, especially those with HIV infection, remains at particular risk and the incidence of hepatocellular carcinoma (HCC) is increasing in th...
https://clinicaltrials.gov/ct2/show/NCT04409340
Feb 1st, 2023 - RESEARCH QUESTION AND BACKGROUND: Primary liver cancer or hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women and is the second cause of cancer mortality worldwide. In Canada, HCC is the only cancer for w...
https://clinicaltrials.gov/ct2/show/NCT01953458
Jan 31st, 2023 - General schedule of the study : Prospective multicenter national study Duration of inclusions:3 years Effective : 25000 patients Duration of the follow-up: 7-8 years Duration of the cohort: 10 years Population : Twenty-five thousands of people wil...
https://clinicaltrials.gov/ct2/show/NCT05676177
Jan 31st, 2023 - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. It affects 25% of the global population, with a higher proportion in Middle Eastern countries, especially in individuals with type 2 diabetes mellitus (T2...
News 566 results
https://www.medscape.com/viewarticle/985272
Dec 8th, 2022 - Intradermal administration of the JYNNEOS mpox vaccine is as effective and safe as subcutaneous administration, according to new data released this week by the Centers for Disease Control and Prevention (CDC). Unvaccinated people were nearly 10 ti...
https://www.medpagetoday.com/hivaids/hivaids/102043
Dec 2nd, 2022 - Drops in HIV testing and pre-exposure prophylaxis (PrEP) prescriptions early on in the pandemic quickly stabilized by the third quarter of 2020, according to a CDC report. The number of HIV tests performed nationally exceeded 2.4 million in the fi...
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/285308
For World Hepatitis Day, learn more about the different types of viral hepatitis that impact millions worldwide and what is being done to help eliminate hepatitis.
https://www.medscape.com/viewarticle/983305
Oct 31st, 2022 - The US Food and Drug Administration (FDA) has declined to approve bulevirtide, Gilead Sciences' drug for the treatment of hepatitis delta virus (HDV) infection and compensated liver disease. In a complete response letter, the FDA voiced concerns o...
https://www.medpagetoday.com/hivaids/hivaids/101238
Oct 14th, 2022 - Reports of stigma and healthcare discrimination run high among Hispanic adults with HIV, according to an analysis of self-reported data from the U.S. in 2018 to 2020. Of 2,690 people interviewed, the overall median HIV stigma score was 31.7 on a s...